Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.030-1.090 for the period, compared to the consensus earnings per share estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.1 billion, compared to the consensus revenue estimate of $5.0 billion. Elanco Animal Health also updated its Q2 2026 guidance to 0.250-0.285 EPS.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, April 27th. Citigroup assumed coverage on Elanco Animal Health in a report on Wednesday, April 15th. They issued a “buy” rating and a $30.00 target price on the stock. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. Morgan Stanley raised their target price on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $27.90.

Elanco Animal Health Stock Performance

Elanco Animal Health stock traded down $2.39 during mid-day trading on Thursday, reaching $23.79. 5,833,868 shares of the company’s stock were exchanged, compared to its average volume of 4,995,441. The business’s fifty day simple moving average is $23.85 and its 200 day simple moving average is $23.33. The firm has a market capitalization of $11.83 billion, a PE ratio of -49.62, a P/E/G ratio of 2.93 and a beta of 1.69. Elanco Animal Health has a one year low of $11.83 and a one year high of $27.72. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.Elanco Animal Health’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period last year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, sell-side analysts expect that Elanco Animal Health will post 1.03 earnings per share for the current year.

Key Headlines Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 beat and raised full?year outlook — Elanco reported adjusted EPS $0.40 and revenue $1.371B, both above consensus, and raised FY 2026 revenue, adjusted EBITDA and adjusted EPS guidance while increasing its innovation revenue target. This reinforces the company’s revenue growth and margin improvement narrative. Elanco Q1 Results & Guidance
• Positive Sentiment: Product approvals and momentum — Elanco received emergency use authorizations for Negasunt Powder and Tanidil, supporting the company’s innovation-led growth story and pipeline credibility. Product Momentum Article
• Neutral Sentiment: Underlying results detail — Q1 revenue rose ~15% YoY (10% organic cc); adjusted EBITDA $334M (24.5% margin); reported net income $57M; adjusted EPS and adjusted EBITDA figures indicate operational progress but GAAP metrics still show limitations. Detailed Results
• Neutral Sentiment: Investor materials available — Earnings slide deck and full call transcript provide management color on product cadence, margin actions and leverage plan for investors doing deeper due diligence. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Q2 EPS guidance misses consensus — Management set Q2 EPS at $0.250–0.285 versus a ~0.290 consensus; this near?term shortfall likely tempered upside despite the stronger FY view. Guidance Details
• Negative Sentiment: Leverage and GAAP profitability remain concerns — Net leverage is still elevated (reported ~3.5x) and the company reports a negative GAAP net margin, so some investors may be cautious until deleveraging and sustained free?cash?flow improvements are clearer. Leverage & Profitability

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in Elanco Animal Health by 5.9% during the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the period. Lazard Asset Management LLC raised its stake in shares of Elanco Animal Health by 0.6% in the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after buying an additional 425 shares during the period. Meeder Advisory Services Inc. raised its stake in shares of Elanco Animal Health by 4.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after buying an additional 510 shares during the period. NewEdge Advisors LLC raised its stake in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares during the period. Finally, Arkadios Wealth Advisors raised its stake in shares of Elanco Animal Health by 1.2% in the fourth quarter. Arkadios Wealth Advisors now owns 52,868 shares of the company’s stock valued at $1,196,000 after buying an additional 652 shares during the period. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.